FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2237-2247 November 29, 2007 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Schwartz, R. S. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destruction and reduced platelet production. Stimulation of platelet production may be an effective treatment for this disorder.

Methods We conducted a trial in which 118 adults with chronic ITP and platelet counts of less than 30,000 per cubic millimeter who had had relapses or whose platelet count was refractory to at least one standard treatment for ITP were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or 75 mg daily) or placebo. The primary end point was a platelet count of 50,000 or more per cubic millimeter on day 43.

Results In the eltrombopag groups receiving 30, 50, and 75 mg per day, the primary end point was achieved in 28%, 70%, and 81% of patients, respectively. In the placebo group, the end point was achieved in 11% of patients. The median platelet counts on day 43 for the groups receiving 30, 50, and 75 mg of eltrombopag were 26,000, 128,000, and 183,000 per cubic millimeter, respectively; for the placebo group the count was 16,000 per cubic millimeter. By day 15, more than 80% of patients receiving 50 or 75 mg of eltrombopag daily had an increased platelet count. Bleeding also decreased during treatment in these two groups. The incidence and severity of adverse events were similar in the placebo and eltrombopag groups.

Conclusions Eltrombopag increased platelet counts in a dose-dependent manner in patients with relapsed or refractory ITP. (ClinicalTrials.gov number, NCT00102739 [ClinicalTrials.gov] .)

Source Information

From Weill Cornell Medical College of Cornell University, New York (J.B.B., B.P.); Prince of Wales Hospital, Shatin, Hong Kong (G.C.); Georgia Cancer Specialists, Tucker, GA (M.N.S.); Hematology Research Center, Moscow (L.K.); Hôpital La Rabta, Tunis, Tunisia (B.M.); Akademia Medyczna, Bialystok, Poland (J.K.); GlaxoSmithKline, Greenford, United Kingdom (H.H., B.M.), and Collegeville, PA (N.L.S., M.A., J.M.J.); and Barts and the London School of Medicine, London (D.P.).

Address reprint requests to Dr. Bussel at Weill Cornell Medical College of Cornell University, 525 E. 68th St., P695, New York, NY 10065, or at jbussel{at}med.cornell.edu.

Full Text of this Article

Related Letters:

Eltrombopag in Thrombocytopenia
Lawson A., Zimmer J., Hentges F., Andrès E., McHutchison J. G., Bussel J. B., Stone N. L., Arning M.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1072-1073, Mar 6, 2008. Correspondence

This article has been cited by other articles:

• Provan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., Grainger, J., Greer, I., Hunt, B. J., Imbach, P. A., Lyons, G., McMillan, R., Rodeghiero, F., Sanz, M. A., Tarantino, M., Watson, S., Young, J., Kuter, D. J. (2010). International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115: 168-186 [Abstract] [Full Text]  
• Psaila, B., Petrovic, A., Page, L. K., Menell, J., Schonholz, M., Bussel, J. B. (2009). Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 114: 4777-4783 [Abstract] [Full Text]  
• Lambert, M. P., Wang, Y., Bdeir, K. H., Nguyen, Y., Kowalska, M. A., Poncz, M. (2009). Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood 114: 2290-2298 [Abstract] [Full Text]  
• Woulfe, D. S. (2009). A Syk inhibitor for sick platelets?. Blood 113: 3133-3134 [Full Text]  
• Podolanczuk, A., Lazarus, A. H., Crow, A. R., Grossbard, E., Bussel, J. B. (2009). Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113: 3154-3160 [Abstract] [Full Text]  
• Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., Bussel, J. B., Cines, D. B., Chong, B. H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M. G., McMillan, R., Sanz, M. A., Imbach, P., Blanchette, V., Kuhne, T., Ruggeri, M., George, J. N. (2009). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113: 2386-2393 [Abstract] [Full Text]  
• Bussel, J. B., Kuter, D. J., Pullarkat, V., Lyons, R. M., Guo, M., Nichol, J. L. (2009). Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113: 2161-2171 [Abstract] [Full Text]  
• Burzynski, J. (2009). New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 66: S11-S21 [Abstract] [Full Text]  
• Gernsheimer, T. (2009). Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis. The Oncologist 14: 12-21 [Abstract] [Full Text]  
• George, J. N., Terrell, D. R. (2008). Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. haematol 93: 1445-1449 [Full Text]  
• Emilia, G., Luppi, M., Morselli, M., Forghieri, F., Potenza, L., Torelli, G. (2008). A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. haematol 93: 1113-1115 [Full Text]  
• Lawson, A., Zimmer, J., Hentges, F., Andres, E., McHutchison, J. G., Bussel, J. B., Stone, N. L., Arning, M. (2008). Eltrombopag in thrombocytopenia.. NEJM 358: 1072-1072 [Full Text]  
• Gernsheimer, T. B. (2008). The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura. ASH Education Book 2008: 219-226 [Abstract] [Full Text]  
• (2007). A New Investigational Drug for Treatment of Thrombocytopenia. JWatch General 2007: 3-3 [Full Text]  
• (2007). New Treatment for Thrombocytopenia. JWatch Oncology and Hematology 2007: 1-1 [Full Text]  
• (2007). What's new in the other general journals. BMJ 335: 1178-1179 [Full Text]  
• McHutchison, J. G., Dusheiko, G., Shiffman, M. L., Rodriguez-Torres, M., Sigal, S., Bourliere, M., Berg, T., Gordon, S. C., Campbell, F. M., Theodore, D., Blackman, N., Jenkins, J., Afdhal, N. H., the TPL102357 Study Group, (2007). Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. NEJM 357: 2227-2236 [Abstract] [Full Text]  
• Schwartz, R. S. (2007). Immune Thrombocytopenic Purpura -- From Agony to Agonist. NEJM 357: 2299-2301 [Full Text]